Intimation regarding receipt of No Objection / No Adverse Observation Letter from The National Stock Exchange of India Limited / BSE Limited in relation to the draft composite scheme of arrangement and amalgamation (merger by absorption) amongst Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, Strides Pharma Services Private Limited and Onesource Specialty Pharma Limited and their respective shareholders (under section 230 to 232 read with section 234, section 52, section 66 of the Indian Companies Act andunder section 210 read with section 212 of The Singapore Companies Act, 1967 and other applicable provisions of the Indian Companies Act, 2013, the Singapore Companies Act, 1967 and the rules framed thereunder ( Proposed Scheme )'.
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Onesource Specialty Pharma has received 'No Objection / No Adverse Observation' letters from both NSE and BSE on February 25, 2026, for its draft composite scheme of arrangement and amalgamation. The scheme involves a multi-step merger where Steriscience Specialties Private Limited will first merge into Brooks Steriscience Limited, after which Brooks Steriscience, Steriscience Pte. Limited (Singapore), and Strides Pharma Services Private Limited will all merge into Onesource. SEBI had earlier provided its comments on February 24, 2026, which both stock exchanges have now incorporated. The observation letters are valid for six months, and the company must file the scheme with the NCLT within this period. The Board had originally approved the proposed scheme on September 26, 2025. The scheme still requires approvals from the NCLT Mumbai, Singapore Court, shareholders, and creditors before it can be implemented.
This is a significant regulatory milestone clearing the way for the merger to move to the NCLT approval stage. Shareholders should note that the scheme is likely to increase promoter shareholding and dilute public shareholding in Onesource, and that accumulated losses of the merging entities will be absorbed into Onesource's balance sheet. The final outcome and share swap ratio will be detailed when the shareholder notice is sent for approval.